Cargando…

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases

The management of RA, SpA, psoriasis and inflammatory bowel disease has significantly improved over the last decade with the addition of tumour necrosis factor inhibitors (anti-TNFs) to the therapeutic armamentarium. Immunogenicity in response to monoclonal antibody therapies (anti-drug antibodies)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jani, Meghna, Barton, Anne, Warren, Richard B., Griffiths, Christopher E. M., Chinoy, Hector
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894670/ https://www.ncbi.nlm.nih.gov/pubmed/23946436 http://dx.doi.org/10.1093/rheumatology/ket260

Ejemplares similares

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice
por: Jani, Meghna, et al.
Publicado: (2016)

Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations
por: Gavan, Sean P, et al.
Publicado: (2020)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study
por: De La Fuente, Fanny, et al.
Publicado: (2022)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2019)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
por: Jani, Meghna, et al.
Publicado: (2017)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
por: Ferrufino, Cheryl P, et al.
Publicado: (2018)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Publicado: (2019)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
por: Edwards, Carl K., et al.
Publicado: (2012)

The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
por: Rutkowski, David, et al.
Publicado: (2019)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
por: Bykerk, Vivian P, et al.
Publicado: (2012)

Infection risk in Rheumatoid Arthritis and Spondyloarthropathy patients under treatment with DMARDs, Corticosteroids and TNF-α antagonists
por: Germano, Valentina, et al.
Publicado: (2014)

Pharmacogenetics of Treatment Response in Psoriatic Arthritis
por: Jani, Meghna, et al.
Publicado: (2015)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Abnormal liver function tests in inflammatory arthritis: think beyond the DMARDs
por: Fahmy, Alexander, et al.
Publicado: (2018)

Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China
por: Gu, Juanfang, et al.
Publicado: (2023)

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2022)

A history of the term “DMARD”
por: Buer, Jonas Kure
Publicado: (2015)

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
por: Mehta, Puja, et al.
Publicado: (2020)

The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry
por: Skácelová, Martina, et al.
Publicado: (2022)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
por: Tobudic, Selma, et al.
Publicado: (2023)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future
por: Zhang, Hongtao, et al.
Publicado: (2020)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD
por: Demase, Kathryn, et al.
Publicado: (2023)

Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies
por: Oldroyd, Alexander, et al.
Publicado: (2018)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Plasma Levels of IL-37 and Correlation with TNF-α, IL-17A, and Disease Activity during DMARD Treatment of Rheumatoid Arthritis
por: Zhao, Ping-Wei, et al.
Publicado: (2014)

Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
por: Hiltunen, J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9mhpvp0f96oe6qqdkf404jsq96